7 April 2020 - Agenus today announced that the U.S. FDA has granted Agenus fast track designation for investigation of balstilimab for the treatment of cervical cancer.
This designation was based on comprehensive data that support the potential for balstilimab to address a significant unmet medical need.
Agenus expects to file two BLAs this year for accelerated approval of the combination of balstilimab and zalifrelimab and balstilimab monotherapy in metastatic cervical cancer.